Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Janne Suhonen
Institution:
Orion Corporation (Finland)
Observed institution:
Orion Corporation (Finland)
ORCID:
0009-0005-3294-3868
Observed ORCID:
0009-0005-3294-3868
OpenAlex ID:
A5132889585
Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models
2024
·
Noora Lehtinen
, Janne Suhonen
, et al.
·
Translational Oncology
·
6
PDF
Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma
2026
·
Eetu Välimäki
, Erika Alanne
, et al.
·
Biomedicine & Pharmacotherapy
PDF
Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A)
2026
·
Kiesha Rice
, Noora Lehtinen
, et al.
·
Journal of Molecular Medicine
PDF
Abstract 3005: Ex vivo trial of ODM-212, a novel pan-TEAD inhibitor, in patients with primary and metastatic solid tumors
2026
·
Juha K. Rantala
, Eetu Välimäki
, et al.
·
Cancer Research
Functional and molecular characterization of the first large cell neuroendocrine prostate cancer cell line
2026
·
Noora Lehtinen
, Janne Suhonen
, et al.
·
Current Molecular Pharmacology
PDF
Show more works
View as search
Works count:
5
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type